Central Lab Services/Clinical Trial Lab Services Market

The report "Central Lab Services/Clinical Trial Lab Services Market by Phase (Phase I, II, III), Service Type (Safety Testing, Immunology), Therapeutic Area (Oncology), Modality (Small Molecules, Vaccine), End user (Pharma & CROs) & Region - Global Forecast to 2030"Global Central lab services/clinical trial lab services market is valued at an estimated USD 5.97 billion in 2025. The size is projected to reach USD 8.18 billion by 2030, at a CAGR of 6.5%.

Browse 317 market data Tables and 47 Figures spread through 310 Pages and in-depth TOC on "Central Lab Services/Clinical Trial Lab Services Market by Phase (Phase I, II, III), Service Type (Safety Testing, Immunology), Therapeutic Area (Oncology), Modality (Small Molecules, Vaccine), End user (Pharma & CROs) & Region - Global Forecast to 2030"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/central-lab-services-market-106848348.html

The market for central lab services/clinical trial lab services is fueled by the increasing prevalence of rare diseases such as sickle cell disease, cystic fibrosis, Duchenne Muscular Dystrophy (DMD), and among others. Additionally, the upsurging number of clinical trials is boosting the market for central lab services/clinical trial lab services. However, the shortage of skilled professionals is restraining the market growth during the forecast period. Additionally, the growing number of emerging markets across the globe to pose as an opportunistic factor for the market growth. But the risk associated with the central lab services/clinical trial lab services such as cybersecurity or intellectual property concerns are challenging the growth of central lab services/clinical trial lab services market across the forecast period.

By phase, phase III segment to grow at the fastest rate in the Central lab services/clinical trial lab services market across the forecast period.

On the basis of phase, the central lab services/clinical trial lab services market is divided into phase I, phase II, phase III, and phase IV. Among these, phase III holds the largest market share in 2024 due to the diverse representation in the clinical trials that will ensure treatments effective to different demographics. The central labs are important during the phase III trials, as it provides comprehensive testing services which includes biomarker analysis, genomic testing and high level of screening, which help in collecting consistent, accurate data from multiple trial sites. In this trial a larger number of participants are required to understand the trial effectively. Additionally, as Phase III trials are the final step before seeking regulatory approval, the quality of data collected is paramount. The need for regulatory compliance, data integrity, and rapid, large-scale testing drives the significant reliance on central lab services in this phase, making it the largest segment in the market. Consequently, the increasing need for this clinical trial has contributed to the segmental growth in the central lab services/clinical trial lab services market.

By end user, Pharmaceutical & Biopharmaceutical Companies holds the largest share in the Central lab services/clinical trial lab services market in 2024.

Based on end user, the central lab services/clinical trial lab services market is segmented into pharmaceutical & biopharmaceutical companies, CROS, medical device companies, and other end users. Among these pharmaceutical & biopharmaceutical companies are holding the largest share in central lab services/clinical trial lab services market in 2024, owing to increasing investments in R&D and various disease awareness campaigns. Additionally, the increasing funding programs such as grants, and government initiative is increasing the number of clinical trials the globe. Considering stringent regulatory compliance associated with central lab clinical trial service, skilled healthcare professionals are required.

North America dominates the global Central lab services/clinical trial lab services market in 2024.

The central lab services/clinical trial lab services market is segmented into five major regional segments, namely, North America, Europe, Asia Pacific, Latin America, Middle East & Africa. The north America accounts for the largest market share of 43.8% in the central lab services/clinical trial lab services market in 2024. This is due to increasing prevalence of cardiovascular diseases, chronic kidney diseases, and among others. For instance, as per Center for diseases control and prevention (CDC) data published in October 2024, one person dies every thirty three seconds of cardiovascular diseases. This shows that there is increasing hospitalization for long-term therapy, thus leading to rising need of new drug and clinical trials. Additionally, the huge presence of central lab services/clinical trial lab services manufacturing companies in the region is increasing the market growth in the region. These companies are investing heavily in research and developments thus providing technologically advanced vascular access devices across the region thus contributing to the regional growth.

Key Players

Prominent players in the Central lab services/clinical trial lab services market include, Thermo Fisher Scientific Inc. (US), IQVIA (US), ICON plc (Ireland), Labcorp (US), Quest Diagnostics (US), Charles River Laboratories (US), Medpace (US), Frontage lab (US), SGS Société Générale de Surveillance SA (Switzerland), Eurofins Scientific (Luxembourg), REPROCELL Inc. (Japan), and ACM Global Laboratories (US).

Don’t miss out on business opportunities in Central Lab Services/Clinical Trial Lab Services Market. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

In addition, MarketsandMarkets SalesIQ enables sales teams to identify high-priority accounts and uncover hidden opportunities, helping them build more pipeline and win more deals with precision.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/